{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002739","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-15T20:27:48+00:00","discovered_at":"2026-05-15T20:32:00.287724+00:00","generated_at":"2026-05-15T20:33:33.627526+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion Therapeutics enters inducement agreement for exercise of ~2M warrants at $0.50, raising ~$1M","bullets":["Holders of 1,995,092 existing warrants (Series A/B at $4.00, Prior Inducement at $11.32) agree to exercise at reduced price of $0.50 per share.","Gross proceeds of approximately $1.0 million expected from the warrant exercise, with H.C. Wainwright as placement agent earning 7% cash fee.","Company will issue new Series C (2,045,000) and Series D (1,945,184) warrants exercisable at $0.50, totaling 3,990,184 new warrant shares.","Closing expected on or about May 18, 2026, with net proceeds used for general corporate purposes.","Placement agent also receives warrants to purchase up to 139,656 ordinary shares at $0.625 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002739","json":"https://secwatch.observer/filing/0001178913-26-002739.json","markdown":"https://secwatch.observer/filing/0001178913-26-002739.md","text":"https://secwatch.observer/filing/0001178913-26-002739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/0001178913-26-002739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/zk2635351.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T20:33:33.627526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"419ccfdd2ae979aabbfe3ba3e12fb6413cec7333","claim":"Silexion Therapeutics Corp entered into Inducement Letter with certain holders valued at approximately $1.0 million (effective 2026-05-15).","evidence_excerpt":"On May 15, 2026, Silexion Therapeutics Corp (“ Silexion ” or the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (each a “ Holder ”) of 1,995,092 of the Company’s existing warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002739/0001178913-26-002739-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain holders"},{"label":"Value","value":"approximately $1.0 million"},{"label":"Effective","value":"2026-05-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}